Skip to NavigationSkip to content

News

0
FDA approves Alexion's Ultomiris in atypical haemolytic uremic syndrome for adults and children
The FDA has moved to expand the existing label for Alexion’s Ultomiris (ravulizumab-cwvz) to include the treatment of atypical haemolytic uremic...
0
CHMP recommends several drugs for EU market approval
The EMA’s human medicines committee (CHMP) has recommended seven medicines for approval at its October 2019 meet including MSD’s Ervebo, AbbVie’s...
0
Roche's Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma
New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq  in combination with Avastin in the treatment of unresectable...
0
AstraZeneca receives FDA approval for Farxiga
AstraZeneca have announced that the US FDA has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure in adults...
>> More News Stories

Features

“No deal” Brexit and life sciences: What happens?

Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite the best efforts of UK...

>> More Features
>> More News Stories